Literature DB >> 17699843

Pseudohypoxic pathways in renal cell carcinoma.

Gennady Bratslavsky1, Sunil Sudarshan, Len Neckers, W Marston Linehan.   

Abstract

Mutations of the von Hippel-Lindau (VHL) or fumarate hydratase (FH) genes lead to morphologically different renal cell carcinomas with distinct clinical courses and outcomes. The VHL protein is a part of an ubiquitin ligase complex that targets proteins for proteosomal degradation. FH is one of the mitochondrial enzymes of the Kreb's cycle. Despite two different functionalities and cellular locations, loss of either VHL or FH products has been shown to alter expression levels of hypoxia-inducible factors (HIF-1alpha and HIF-2alpha) and their downstream targets. HIF proteins are key regulators of oxygen homeostasis. Tight regulation of HIF allows for cell survival and growth at the time of hypoxic stress. HIF acts via transcriptional regulation of vascular endothelial growth factor, platelet derived growth factor, endothelial growth factor receptor, glucose transporter protein 1, erythropoietin, and transforming growth factor-alpha. Loss of VHL or FH is thought to result in a pseudohypoxic state so that cellular response pathways mediated by HIF are activated despite normal oxygen conditions. Understanding of these pseudohypoxic pathways has provided a better appreciation of the molecular mechanisms of carcinogenesis in addition to providing a rationale for targeted therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699843     DOI: 10.1158/1078-0432.CCR-06-2510

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  Molecular targets for cancer chemoprevention.

Authors:  William N William; John V Heymach; Edward S Kim; Scott M Lippman
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

2.  Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney.

Authors:  Alexander Wolfe; Sheila M Dobin; Petr Grossmann; Michal Michal; Ludvik R Donner
Journal:  Virchows Arch       Date:  2011-08-07       Impact factor: 4.064

Review 3.  Targeted therapies for non-clear renal cell carcinoma.

Authors:  Eric A Singer; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Target Oncol       Date:  2010-08-03       Impact factor: 4.493

Review 4.  Oncometabolites in renal cancer.

Authors:  Cissy Yong; Grant D Stewart; Christian Frezza
Journal:  Nat Rev Nephrol       Date:  2019-10-21       Impact factor: 28.314

5.  The changing face of renal-cell carcinoma.

Authors:  Gennady Bratslavsky; Ziya Kirkali
Journal:  J Endourol       Date:  2010-05       Impact factor: 2.942

6.  Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.

Authors:  Mei Yee Koh; Vuvi Nguyen; Robert Lemos; Bryant G Darnay; Galina Kiriakova; Mena Abdelmelek; Thai H Ho; Jose Karam; Federico A Monzon; Eric Jonasch; Garth Powis
Journal:  Cancer Res       Date:  2014-11-24       Impact factor: 12.701

7.  Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia.

Authors:  Katarína Smolková; Nadège Bellance; Francesca Scandurra; Elisabeth Génot; Erich Gnaiger; Lydie Plecitá-Hlavatá; Petr Jezek; Rodrigue Rossignol
Journal:  J Bioenerg Biomembr       Date:  2010-01-19       Impact factor: 2.945

Review 8.  Impact of heat-shock protein 90 on cancer metastasis.

Authors:  Shinji Tsutsumi; Kristin Beebe; Len Neckers
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

9.  Targeting cancer metabolism.

Authors:  Beverly A Teicher; W Marston Linehan; Lee J Helman
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

10.  Feasibility and outcomes of repeat partial nephrectomy.

Authors:  Aaron Johnson; Sunil Sudarshan; Jack Liu; W Marston Linehan; Peter A Pinto; Gennady Bratslavsky
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.